ISSN: 1875-6417 (Online)
ISSN: 1573-3998 (Print)
Volume 12, 4 Issues, 2016
Download PDF Flyer
Underlying Pathways for Interferon Risk to Type II Diabetes Mellitus
Current Diabetes Reviews, 9
): 472-477.Author(s): Nabil Abdel-Hamid
, Taghreed Al Jubori
, Amaal Farhan
, Mariam Mahrous
, Adel Gouri
, Ezzat Awad
and Johannes Breuss
Dean of College of Pharmacy, Kafrelsheikh University, Egypt.
Purchase Online Order Reprints Order Eprints Rights and Permissions
It has been known that chronic liver treatments interfere with blood glucose metabolism. It was recognized that diabetes mellitus among chronic hepatitis C was greater in other types of chronic liver diseases. Hepatitis C directly promotes insulin resistance through the proteosomal degradation of insulin resistance substrate. It suppressed hepatocyte glucose uptake through down-regulation of surface expression of glucose transporter. Long-term exposure to cytokine over expression seems to be cytotoxic to both beta cells of the pancreas and to hepatocytes. Elevated tumor necrosis factor-a, or its neutralization, increased insulin sensitivity. Interferon-a may also elevate the serum level of interleukin-1 which is cytotoxic to pancreatic islet cells. Both Diabetes mellitus and resistance to interferon-a therapy are abnormally mediated by over-expression of suppressor of cytokine signaling-1 in hepatocytes of chronic hepatitis C patients.
Conclusion: These data suggest that interferon-a therapy should be administered with caution in patients showing any predisposition to Diabetes mellitus. Anti inflammatory therapy is critically recommended as a protector against disease development due to cytokine mediated Diabetes mellitus during hepatitis C therapy, since inflammation seems to be a main candidate to interferon suspected diabetogenesis.